ConductScience.org, home

Paper41245385

Integrated analysis of the safety of fecal microbiota, live-jslm in adults with recurrent Clostridioides difficile infection from five prospective clinical trials: an update.

Lee C and 9 others. Ther Adv Gastroenterol, 2025. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. Integrated analysis of the safety of fecal microbiota, live-jslm in adults with recurrent Clostridioides difficile infection from five prospective clinical trials: an update. Papers, record 41245385. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41245385

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Integrated analysis of the safety of fecal microbiota, live-jslm in adults with recurrent Clostridioides difficile infection from five prospective clinical trials: an update.
PubMed
Journal
Ther Adv Gastroenterol
PubMed
Year
2025
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-09-18
PubMed

Authors10

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Lee CChristinehttps://orcid.org/0000-0002-0014-7788
2Feuerstadt PPaulhttps://orcid.org/0000-0002-7643-9576
3Louie TThomas
4Bancke LLindy
5Guthmueller BBeth
6Harvey AAdam
7Hoeyer FFrederikke
8Orenstein RRoberthttps://orcid.org/0000-0001-5210-1258
9Dubberke ERErik R
10Khanna SSahil

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Trials5

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's recordSource
NCT01925417Microbiota Restoration Therapy for Recurrent Clostridium Difficile-associated DiarrheaDerived from the trialYesClinicalTrials.gov
NCT02299570Microbiota Restoration Therapy for Recurrent Clostridium Difficile InfectionDerived from the trialYesClinicalTrials.gov
NCT02589847Microbiota Restoration Therapy for Recurrent Clostridium Difficile InfectionDerived from the trialYesClinicalTrials.gov
NCT03244644Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCHCD3)Derived from the trialYesClinicalTrials.gov
NCT03931941Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCH CD3-OLS)Derived from the trialYesClinicalTrials.gov

Download CSV of trials

References16

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
140277958The Global Burden of Clostridioides difficile Infections, 2016-2024: A Systematic Review and Meta-Analysis.Infect Dis Rep2025https://conductscience.org/library/papers/40277958PubMed
238395525AGA Clinical Practice Guideline on Fecal Microbiota-Based Therapies for Select Gastrointestinal Diseases.Gastroenterology2024https://conductscience.org/library/papers/38395525PubMed
329617739Results From a Randomized, Placebo-Controlled Clinical Trial of a RBX2660-A Microbiota-Based Drug for the Prevention of Recurrent Clostridium difficile Infection.Clin Infect Dis2018https://conductscience.org/library/papers/29617739PubMed
433995583Evolution of clinical guidelines for antimicrobial management of Clostridioides difficile infection.Ther Adv Gastroenterol2021https://conductscience.org/library/papers/33995583PubMed
536287379
Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection.
Drugs2022https://conductscience.org/library/papers/36287379PubMed
636544075Final Results from a Phase 2b Randomized, Placebo-Controlled Clinical Trial of RBX2660: A Microbiota-Based Drug for the Prevention of Recurrent Clostridioides difficile Infection.Infect Dis Ther2023https://conductscience.org/library/papers/36544075PubMed
739180326
PUNCH CD3-OLS: A Phase 3 Prospective Observational Cohort Study to Evaluate the Safety and Efficacy of Fecal Microbiota, Live-jslm (REBYOTA) in Adults With Recurrent Clostridioides difficile Infection.
Clin Infect Dis2025https://conductscience.org/library/papers/39180326PubMed
840784972Safety and Efficacy of Fecal Microbiota, Live-jslm to Prevent Recurrent Clostridioides difficile Infection in Participants With Irritable Bowel Syndrome.Infect Dis Ther2025https://conductscience.org/library/papers/40784972PubMed
926565008Safety and Durability of RBX2660 (Microbiota Suspension) for Recurrent Clostridium difficile Infection: Results of the PUNCH CD Study.Clin Infect Dis2016https://conductscience.org/library/papers/26565008PubMed
1036882700The burden of CDI in the United States: a multifactorial challenge.BMC Infect Dis2023https://conductscience.org/library/papers/36882700PubMed
1140177588
Safety and Efficacy of Fecal Microbiota, Live-jslm, in Preventing Recurrent Clostridioides difficile Infection in Participants Who Were Mildly to Moderately Immunocompromised in the Phase 3 PUNCH CD3-OLS Study.
Open Forum Infect Dis2025https://conductscience.org/library/papers/40177588PubMed
1239862395Safety and Efficacy of Fecal Microbiota, Live-jslm (REBYOTA®), for the Prevention of Recurrent Clostridioides difficile Infection in Participants With Inflammatory Bowel Disease in PUNCH CD3-OLS.Inflamm Bowel Dis2025https://conductscience.org/library/papers/39862395PubMed
1323804381Intestinal dysbiosis and depletion of butyrogenic bacteria in Clostridium difficile infection and nosocomial diarrhea.J Clin Microbiol2013https://conductscience.org/library/papers/23804381PubMed
1437333464Safety of fecal microbiota, live-jslm (REBYOTA™) in individuals with recurrent Clostridioides difficile infection: data from five prospective clinical trials.Ther Adv Gastroenterol2023https://conductscience.org/library/papers/37333464PubMed
1532242357Trends in U.S. Burden of Clostridioides difficile Infection and Outcomes.N Engl J Med2020https://conductscience.org/library/papers/32242357PubMed
1635279084Durable reduction of Clostridioides difficile infection recurrence and microbiome restoration after treatment with RBX2660: results from an open-label phase 2 clinical trial.BMC Infect Dis2022https://conductscience.org/library/papers/35279084PubMed

Download CSV of references

Cited by1

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 0 citations.

PMIDTitleJournalYearIn Papers
42840322Evaluation of fecal microbiota, live (RBL) for the prevention of recurrent Clostridioides difficile infection: Canadian subgroup analysis of an open-label phase 3 study.J Can Assoc Gastroenterol2026https://conductscience.org/library/papers/42840322

Source PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41245385

GET https://conductscience.org/api/papers/v1/41245385/authors